Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHI-202
- Development stage
- Unknown
- Administration
- Oral
01
Overview
CHI-202 is an investigational powder formulation administered orally and studied for its effects on safety, tolerability, and relief of symptoms associated with delayed onset muscle soreness (DOMS) after exercise. Participants in clinical trials consumed a 7g sachet of CHI-202 powder dissolved in water twice daily. The mechanism of action, molecular class, and specific constituents are not disclosed in public sources as of this date. The drug’s development status is consistent with early-phase clinical testing, focusing on reduction of soreness, discomfort, and stiffness post-exercise, as well as monitoring vital signs and adverse events[1].
- Brand names
- CHI-202CHI202CHI 202
- Other names
- CHI-202CHI202CHI 202
Beyond the preview
Go deeper on CHI-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHI-202.